Pipeline

Rain intends to build a targeted oncology platform, with the first program, tarloxotinib (Tarlox), holding promise across various indications

Tarlox Development Overview

DiscoveryPreclinicalPhase 1Phase 2
NSCLC
Pan-Tumor
Pan-Tumor

Trial recruiting

1. Includes EGFR kinase domain duplications (KDD), EGFR fusions, ERBB2, and ERBB4 fusions